Average Co-Inventor Count = 4.23
ph-index = 1
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Nammi Therapeutics, Inc. (9 from 9 patents)
2. Qwixel Therapeutics LLC (2 from 2 patents)
11 patents:
1. 12311010 - Formulated and/or co-formulated liposome compositions containing toll-like receptor('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof
2. 12286403 - Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
3. 12162958 - Fusion protein composition(s) comprising masked type i interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
4. 12059470 - Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
5. 11896646 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof
6. 11833209 - Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
7. 11801304 - Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof
8. 11795198 - Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
9. 11744874 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof
10. 11679141 - Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof
11. 11136353 - Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof